NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

  • October 29, 2024
  • Home
  • USA
  • NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow

You May Also Like

WBTN DEADLINE: ROSEN, SKILLE ...

November 1, 2024

First National Bank Alaska d ...

November 1, 2024

HeartFlow Announces New Deci ...

November 1, 2024